Loxo Oncology Inc (NASDAQ:LOXO) – Investment analysts at Oppenheimer issued their FY2017 EPS estimates for Loxo Oncology in a report issued on Wednesday. Oppenheimer analyst L. Cann expects that the biopharmaceutical company will earn ($5.84) per share for the year. Oppenheimer has a “Outperform” rating and a $132.00 price objective on the stock. Oppenheimer also issued estimates for Loxo Oncology’s Q4 2018 earnings at ($0.81) EPS, FY2018 earnings at ($4.48) EPS, FY2019 earnings at ($7.56) EPS and FY2020 earnings at ($9.65) EPS.
Other equities research analysts have also recently issued reports about the company. Zacks Investment Research upgraded Loxo Oncology from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. BidaskClub upgraded Loxo Oncology from a “buy” rating to a “strong-buy” rating in a research report on Saturday. CIBC assumed coverage on Loxo Oncology in a research report on Thursday. They set an “outperform” rating and a $132.00 price target on the stock. William Blair assumed coverage on Loxo Oncology in a research report on Tuesday, November 28th. They set an “outperform” rating on the stock. Finally, Citigroup decreased their price target on Loxo Oncology from $112.00 to $108.00 and set a “buy” rating on the stock in a research report on Thursday, November 16th. One equities research analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the company. The stock has an average rating of “Buy” and a consensus price target of $108.89.
Several hedge funds and other institutional investors have recently modified their holdings of LOXO. QS Investors LLC purchased a new position in shares of Loxo Oncology during the fourth quarter worth about $118,000. Quantbot Technologies LP purchased a new position in shares of Loxo Oncology during the third quarter worth about $122,000. Ameritas Investment Partners Inc. grew its holdings in shares of Loxo Oncology by 31.3% during the second quarter. Ameritas Investment Partners Inc. now owns 1,758 shares of the biopharmaceutical company’s stock worth $141,000 after purchasing an additional 419 shares in the last quarter. Xact Kapitalforvaltning AB purchased a new position in shares of Loxo Oncology during the fourth quarter worth about $208,000. Finally, Cambridge Investment Research Advisors Inc. purchased a new position in shares of Loxo Oncology during the third quarter worth about $212,000.
In other news, CEO Joshua H. Bilenker sold 15,000 shares of the business’s stock in a transaction dated Tuesday, November 28th. The stock was sold at an average price of $74.45, for a total transaction of $1,116,750.00. Following the completion of the transaction, the chief executive officer now owns 182,707 shares of the company’s stock, valued at $13,602,536.15. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Naarden Jacob Van sold 3,082 shares of the business’s stock in a transaction dated Tuesday, November 28th. The stock was sold at an average price of $74.50, for a total value of $229,609.00. Following the transaction, the insider now directly owns 1,541 shares of the company’s stock, valued at approximately $114,804.50. The disclosure for this sale can be found here. Insiders have sold 602,228 shares of company stock valued at $49,640,087 in the last three months. 44.40% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This report was originally reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this report on another publication, it was illegally copied and reposted in violation of United States & international trademark & copyright laws. The legal version of this report can be viewed at https://www.tickerreport.com/banking-finance/3222190/loxo-oncology-inc-loxo-forecasted-to-post-fy2017-earnings-of-5-84-per-share.html.
About Loxo Oncology
Loxo Oncology, Inc is a biopharmaceutical company. The Company is focused on development of medicines for patients with genetically defined cancers. The Company’s pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect.
Receive News & Ratings for Loxo Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Loxo Oncology and related companies with MarketBeat.com's FREE daily email newsletter.